easyseptm human cd138 positive selection kit ii (STEMCELL Technologies Inc)
90
Structured Review
STEMCELL Technologies Inc
easyseptm human cd138 positive selection kit ii
Easyseptm Human Cd138 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/easyseptm+human+cd138+positive+selection+kit+ii/human+cd138+positive+selection+kit/pmc11866523-43-0-8
Average 90 stars, based on 1 article reviews
Easyseptm Human Cd138 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/easyseptm+human+cd138+positive+selection+kit+ii/human+cd138+positive+selection+kit/pmc11866523-43-0-8
Average 90 stars, based on 1 article reviews
easyseptm human cd138 positive selection kit ii - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets"
Article Title: Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2024.101925
Figure Legend Snippet: Inter-patient heterogeneity (A) UMAPs representing scRNA-seq data from enriched PCs from all patients with color codes representing unique samples (left), mPC and pPC populations (middle), and mPCs and pPCs by diagnosis (right). (B) Number of genes detected as dysregulated with a log2 FC of ≥ 0.5 or ≤ −0.5 when the analysis was conducted using all CD138 + PCs, or CD138 + mPCs from each sample identified by scBCR-seq, using “ FindAllMarkers ” in Seurat. Horizontal lines indicate little to no difference in the number of DEGs, while upward lines indicate more DEGs found when the analysis focused only on the mPCs. ∗ indicates p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p ≤ 0.0001; and n.s. non-significant differences, as determined by the Wilcoxon test. (C) UMAP based on the single-cell transcriptome of a downsampled Seurat object with a color code of CytoTRACE score (left), and a superplot of the mean CytoTRACE score per sample group by diagnosis (right). Statistical testing was performed as in (B). (D) Boxplot of normalized UMIs detected in each sample, color coded by diagnosis, including myeloma-related markers, and commonly up- and down-regulated markers. (E) Heatmap of the fraction of PCs with myeloma IGH translocations detected by FISH (top), and boxplots of normalized UMIs of associated oncogene expression levels (next three rows). (F) Circos plots of three t(11;14) + myelomas evaluated by Lumpy using WGS data from germline and tumor-matched samples. (G) Heatmap of the fraction of cells with inferred large chromosomal gains (red) or losses (blue) in each PC population organized by diagnosis. Total number of PCs isolated and the fraction of mPCs in each sample are represented at the top. These plots include a dataset of pPC samples ( n = 4), and mPCs from patients with MGUS ( n = 11), SMM ( n = 22), NDMM ( n = 17), RRMM ( n = 15), and PCL ( n = 2).
Techniques Used: Biomarker Discovery, Expressing, Isolation
Figure Legend Snippet:
Techniques Used: Recombinant, Selection, Cell Isolation, Proliferation Assay, Staining, Enzyme-linked Immunosorbent Assay, Detection Assay, Reporter Assay, RNA Sequencing, Transgenic Assay, Software
Related Articles
Isolation:Article Title: Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Article Snippet: .. CD138+ cells were isolated from five healthy volunteers and three unique MM patients PBMCs using Article Title: Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity Article Snippet: 1 Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity Priyanka S. Rana 1,2* , James J. Ignatz-Hoover 1,2 , Chunna Guo 3,4 , Amber L. Mosley 3,4 , Ehsan Malek 1,2,5 , Yuriy Federov 6 , Drew J. Adams 6 and James J. Driscoll 1,2,5† 1 Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH 2 Division of Hematology & Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH 3 Center for Proteome Analysis, Indiana University School of Medicine, Indianapolis, IN 4 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 5 Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 6 Small Molecule Drug Discovery Core, Case Western Reserve University, Cleveland, OH † Corresponding author: 2103 Cornell Road, WRB 2-126, Cleveland, OH, 216-368-0933; James.Driscoll@UHhospitals.org Running title: Immunoproteasome activators unmask neoantigen presentation The authors declare no potential conflicts of interest Conflict of Interest Statement.. The authors state that the manuscript was prepared without any commercial or financial relationships and without any conflict of interest.. Word count: Abstract- 250; Words- 3,988 References: 69 Figures: 7; Supplementary Tables: 4; Supplementary Figures: 9 D ow nloaded from http://aacrjournals.org/m ct/article-pdf/doi/10.1158/1535-7163.M C T-23-0931/3491428/m ct-23-0931.pdf by guest on 12 Septem ber 2024 2 Proteasomes generate antigenic peptides that are presented on the tumor surface to cytotoxic Tlymphocytes (CTLs). Article Title: A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma. Article Snippet: .. In brief, bone marrow mononuclear cells (BMMCs) were isolated using lymphoprep® (Axis-Shield, Dundee, United Kingdom) density gradient centrifugation and CD138+ cells were isolated from the BMMCs by positive selection using the Selection:Article Title: Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Article Snippet: .. CD138+ cells were isolated from five healthy volunteers and three unique MM patients PBMCs using Article Title: Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity Article Snippet: 1 Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity Priyanka S. Rana 1,2* , James J. Ignatz-Hoover 1,2 , Chunna Guo 3,4 , Amber L. Mosley 3,4 , Ehsan Malek 1,2,5 , Yuriy Federov 6 , Drew J. Adams 6 and James J. Driscoll 1,2,5† 1 Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH 2 Division of Hematology & Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH 3 Center for Proteome Analysis, Indiana University School of Medicine, Indianapolis, IN 4 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 5 Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 6 Small Molecule Drug Discovery Core, Case Western Reserve University, Cleveland, OH † Corresponding author: 2103 Cornell Road, WRB 2-126, Cleveland, OH, 216-368-0933; James.Driscoll@UHhospitals.org Running title: Immunoproteasome activators unmask neoantigen presentation The authors declare no potential conflicts of interest Conflict of Interest Statement.. The authors state that the manuscript was prepared without any commercial or financial relationships and without any conflict of interest.. Word count: Abstract- 250; Words- 3,988 References: 69 Figures: 7; Supplementary Tables: 4; Supplementary Figures: 9 D ow nloaded from http://aacrjournals.org/m ct/article-pdf/doi/10.1158/1535-7163.M C T-23-0931/3491428/m ct-23-0931.pdf by guest on 12 Septem ber 2024 2 Proteasomes generate antigenic peptides that are presented on the tumor surface to cytotoxic Tlymphocytes (CTLs). Article Title: Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets Article Snippet: .. Article Title: Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity. Article Snippet: .. The selection of CD138-negative cells was performed by Article Title: Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Article Snippet: Upon reception, 60 μL of DNA stabilizer (Bionano genomics, San Diego, CA, USA) was added to all fresh BMA samples. .. Plasma cells were then purified using Article Title: A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma. Article Snippet: .. In brief, bone marrow mononuclear cells (BMMCs) were isolated using lymphoprep® (Axis-Shield, Dundee, United Kingdom) density gradient centrifugation and CD138+ cells were isolated from the BMMCs by positive selection using the Clinical Proteomics:Article Title: Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Article Snippet: Upon reception, 60 μL of DNA stabilizer (Bionano genomics, San Diego, CA, USA) was added to all fresh BMA samples. .. Plasma cells were then purified using Purification:Article Title: Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Article Snippet: Upon reception, 60 μL of DNA stabilizer (Bionano genomics, San Diego, CA, USA) was added to all fresh BMA samples. .. Plasma cells were then purified using Gradient Centrifugation:Article Title: A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma. Article Snippet: .. In brief, bone marrow mononuclear cells (BMMCs) were isolated using lymphoprep® (Axis-Shield, Dundee, United Kingdom) density gradient centrifugation and CD138+ cells were isolated from the BMMCs by positive selection using the |